# Safety and Efficacy of γδ T Cell Against Gastric Cancer

> **NCT02585908** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Beijing Doing Biomedical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **BIOLOGICAL:** CIK
- **BIOLOGICAL:** γδ T
- **BIOLOGICAL:** CIK and γδ T

## Key facts

- **NCT ID:** NCT02585908
- **Lead sponsor:** Beijing Doing Biomedical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-12
- **Primary completion:** 2021-12
- **Final completion:** 2022-12
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2019-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02585908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02585908, "Safety and Efficacy of γδ T Cell Against Gastric Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02585908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*